Orforglipron: Advancing Multifunctional Therapeutic Applications and Synthesis Innovations in GLP-1R Targeting

Orforglipron is a small molecule drug that targets the GLP-1R, with therapeutic applications in Nervous System Diseases, Cardiovascular Diseases, Endocrinology and Metabolic Disease, Respiratory Diseases, and Urogenital Diseases. 

Orforglipron's focus on a wide range of therapeutic areas indicates its potential as a multi-functional drug, addressing conditions in various systems of the body. Its targeting of the GLP-1R suggests a potential impact on metabolic and endocrine functions, as well as potential cardiovascular and respiratory benefits.

Log in to the Patsnap Chemical. Select the Multi-Structure search, and search for the reactants and products in the specific steps of the synthesis route of Orforglipron. click on search references, and you can query the relevant literature. 

Linked to the Patsnap patent, check the 'Chemistry' category under the technical subject classification and click on the filter, which will allow you to accurately retrieve the design and improvement of the Orforglipron process route by Eli Lilly & Co. and other companies，Such as Eli Lilly & Co.'s international patent WO2024137426A1 (application date 20231218, publication date 20240627) describes a process for making a GLP1RA receptor agonist(Orforglipron), which is a pharmaceutically acceptable salt. The process involves several steps and intermediates, resulting in a more robust and efficient process compared to previous methods. Additionally, SHANGHAI SUBO PHARM TECH CO LTD 's patent CN117777111A (application date 20231226, publication date 20240329) provides a new synthesis method of Orforglipron key intermediates and its intermediates. Through this method, the synthesis cost can be reduced, the feasibility of the synthesis is improved, and the possibility of expanding mass production is provided.

The drug's highest phase of development at Phase 3 in both global and Chinese markets indicates a certain level of maturity in its clinical development, suggesting that it has already undergone rigorous testing for safety and efficacy. This signals a significant level of investment and commitment from the originator organization, Chugai Pharmaceutical Co., Ltd.

Overall, the development of Orforglipron as a small molecule drug targeting the GLP-1R represents a promising advancement in the field of biomedicine, with the potential to address diverse and prevalent medical conditions.

AI built to maximize IP and R&D efficiency

Redefine chemical FTO with a range of structure retrieval options at your fingertips, from exact matches to similarity searches, all powered by deep data processing techniques and proprietary AI algorithms to eliminate the risk of omitting key results.